Similar to the approach employing a PARP inhibitor targeting BRCA1 mutations in breast and ovarian cancers [4], several preclinical studies on the inhibition of ATM have been performed to enhance radio-sensitivity in other solid tumors [5, 6] and high-grade gliomas [7–10]. This evidence concerns the gene BRCA1 and ovarian cancer.